Skip to main content

Table 1 The characteristics of the study population

From: The association among uric acid, microalbumin and estimated glomerular filtration rate in hypertensive patients: a case control study

 

Non-hyperuricemia group (n = 476)

Hyperuricemia group (n = 257)

P

Age, years

44.6 ± 12.7

38.8 ± 10.6

< 0.001

Male, n (%)

312 (65.5)

219 (85.2)

< 0.001

BMI, kg/m2

26.1 ± 3.6

28.7 ± 4.0

< 0.001

Duration of hypertension, months

24 (3, 72)

24 (4, 60)

0.698

Grade of hypertension

  

0.071

  Non-grade 3 hypertension, n (%)

180 (37.8)

80 (31.1)

 

  Grade 3 hypertension, n (%)

296 (62.2)

177 (68.9)

 

Smoking, n (%)

167 (35.1)

103 (40.1)

0.181

Alcohol intake, n (%)

72 (15.1)

40 (15.6)

0.875

Diabetes mellites. n (%)

37 (7.8)

11 (4.3)

0.068

CHD, n (%)

25 (5.3)

4 (1.6)

0.014

Cerebrovascular disease, n (%)

22 (4.6)

3 (1.2)

0.014

Antihypertension drugs intake

   

  ACEI/ARB, n (%)

175 (40.4)

101 (43.5)

0.437

  β-blocker, n (%)

70 (16.2)

26 (11.2)

0.083

  CCB, n (%)

182 (42.0)

99 (42.7)

0.873

  Diuretic, n (%)

47 (10.9)

26 (11.2)

0.890

  α-blocker, n (%)

12 (2.8)

10 (4.3)

0.290

  MRA, n (%)

2 (0.5)

2 (0.9)

0.528

WBC, 109/L

6.2 ± 1.6

6.6 ± 1.7

0.001

RBC, 1012/L

4.8 ± 0.5

5.0 ± 0.4

< 0.001

HGB, g/L

145.7 ± 16.0

152.0 ± 13.4

< 0.001

Fasting glucose, mmol/L

5.2 ± 1.3

5.3 ± 1.4

0.322

2-h glucose, mmol/L

8.8 ± 2.9

8.7 ± 2.5

0.601

TC, mmol/L

4.6 ± 0.9

4.7 ± 0.9

0.025

TG, mmol/L

1.6 ± 1.1

2.3 ± 1.5

< 0.001

HDL-C, mmol/L

1.1 ± 0.3

1.1 ± 0.3

< 0.001

LDL-C, mmol/L

3.0 ± 0.8

3.1 ± 0.8

0.055

Cr, mg/dL

0.7 ± 0.2

0.8 ± 0.2

< 0.001

UA, μmol/L

321.4 ± 63.5

482.3 ± 64.5

< 0.001

Daytime mean SBP, mmHg

134.6 ± 15.2

139.9 ± 16.9

< 0.001

Nighttime mean SBP, mmHg

123.7 ± 17.2

128.4 ± 19.1

0.001

24 h mean SBP, mmHg

132.0 ± 15.0

137.1 ± 16.8

< 0.001

Daytime mean DBP, mmHg

82.6 ± 13.2

86.7 ± 12.8

< 0.001

Nighttime mean DBP, mmHg

73.4 ± 13.2

77.8 ± 13.6

< 0.001

24 h mean DBP, mmHg

80.4 ± 12.8

84.6 ± 12.6

<0.001

24 h urinary sodium, mmol/24 h

146.5 ± 63.2

156.5 ± 63.7

0.047

24 h-MAU, mg/24 h

13.9 (8.4, 27.8)

21.0 (1.0, 44.5)

< 0.001

  ≥ 30 mg/24 h, n (%)

104 (23.3)

94 (37.8)

< 0.001

eGFR, ml·min−1·1.73 m−2

131.6 ± 29.7

119.8 ± 28.5

< 0.001

  < 90 ml·min−1·1.73 m−2, n (%)

26 (5.5)

31 (12.1)

0.001

  < 60 ml·min−1·1.73 m−2, n (%)

2 (0.4)

3 (1.2)

0.241

  1. Categorical data were represented by use numbers (%). Continuous variables conforming to normal distribution were expressed as mean ± standard (x ± s). The median (P25–P75) was used to express the skewed distribution of continuous variables.
  2. BMI: body mass index; ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor inhibitor; CCB: calcium channel blockers; MRA: mineralocorticoid receptor antagonists; WBC: white blood cell; RBC: red blood cell; HGB: hemoglobin; TC: total cholesterol; TG: triglycerides; UA: uric acid; SBP: systolic blood pressure; DBP: diastolic blood pressure; 24 h-MAU: 24-h microalbuminuria; eGFR: estimated glomerular filtration rate
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us